# SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT06208033** · EARLY_PHASE1 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SMET12
- **DRUG:** SMET12
- **DRUG:** SMET12

## Key facts

- **NCT ID:** NCT06208033
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-10
- **Primary completion:** 2024-10-20
- **Final completion:** 2024-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208033, "SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06208033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*